Discontinued — last reported Q4 '25
Year-over-year, this metric declined by 100.0%, from $24.00M to $0.00. Over 4 years (FY 2022 to FY 2026), Acquisitions shows a downward trend with a -100.0% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.03B | $123.00M | $30.50M | $65.20M | $96.00M | $0.00 | $0.00 | $0.00 | $26.00M | $0.00 | $18.00M | $26.00M | $637.00M | $164.00M | $0.00 | $24.00M | $0.00 | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | -88.1% | -75.2% | +113.8% | +47.2% | -100.0% | — | — | — | -100.0% | — | +44.4% | >999% | -74.3% | -100.0% | — | -100.0% | — | — | — |
| YoY Change | — | — | — | — | -90.7% | -100.0% | -100.0% | -100.0% | -72.9% | — | — | — | >999% | — | -100.0% | -7.7% | -100.0% | -100.0% | — | -100.0% |